

# Dolors Colomer

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1190639/dolors-colomer-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

231  
papers

16,461  
citations

61  
h-index

126  
g-index

241  
ext. papers

18,293  
ext. citations

6.7  
avg, IF

5.73  
L-index

#	Paper	IF	Citations
231	Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. <i>Nature Genetics</i> , <b>2005</b> , 37, 391-400	36.3	1492
230	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , <b>2011</b> , 475, 101-5	50.4	1206
229	ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 1764-75	59.2	1093
228	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. <i>Nature Genetics</i> , <b>2011</b> , 44, 47-52	36.3	752
227	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , <b>2015</b> , 526, 519-24	50.4	565
226	Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. <i>Nature Genetics</i> , <b>2012</b> , 44, 1236-42	36.3	422
225	Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. <i>Nature Reviews Cancer</i> , <b>2007</b> , 7, 750-62	31.3	387
224	The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. <i>Blood</i> , <b>2006</b> , 107, 257-64	2.2	385
223	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 18250-5	11.5	377
222	Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. <i>Cancer Research</i> , <b>2010</b> , 70, 1408-18	10.1	373
221	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. <i>Blood</i> , <b>2004</b> , 103, 1237-43 <sup>2</sup>	2.2	338
220	Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. <i>Blood</i> , <b>2003</b> , 101, 78-84	2.2	322
219	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica</i> , <b>2009</b> , 94, 1555-62	6.6	299
218	Molecular pathogenesis of mantle cell lymphoma. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 3416-23	15.9	275
217	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , <b>2014</b> , 124, 1062-9	2.2	268
216	Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2797-804	2.2	205
215	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. <i>Blood</i> , <b>2013</b> , 121, 2734-8	2.2	196

214	Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. <i>Cancer Research</i> , <b>2012</b> , 72, 5307-16	10.1	195
213	Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. <i>Oncogene</i> , <b>2005</b> , 24, 7213-23	9.2	189
212	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. <i>Blood</i> , <b>2016</b> , 127, 2122-30	2.2	188
211	The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. <i>Blood</i> , <b>2007</b> , 109, 4441-9	2.2	177
210	Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. <i>Blood</i> , <b>2001</b> , 98, 2771-7	2.2	175
209	Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. <i>Haematologica</i> , <b>2006</b> , 91, 169-75	6.6	173
208	Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , <b>1998</b> , 92, 1406-1414	2.2	159
207	In Vitro Evaluation of Fludarabine in Combination With Cyclophosphamide and/or Mitoxantrone in B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>1999</b> , 94, 2836-2843	2.2	153
206	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2002</b> , 119, 976-84	4.5	146
205	Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. <i>Genome Research</i> , <b>2014</b> , 24, 212-26	9.7	143
204	Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. <i>Circulation</i> , <b>2003</b> , 107, 2428-34	16.7	138
203	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i> , <b>2008</b> , 112, 3130-4	2.2	129
202	Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. <i>Blood</i> , <b>2002</b> , 99, 2969-76	2.2	123
201	Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. <i>Blood</i> , <b>2003</b> , 101, 3674-80	2.2	121
200	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. <i>Blood</i> , <b>2010</b> , 116, e111-7	2.2	120
199	Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3433-8	2.2	116
198	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , <b>2006</b> , 107, 4563-9	2.2	114
197	Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. <i>Cancer Research</i> , <b>2006</b> , 66, 6947-54	10.1	111

196	SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. <i>Blood</i> , <b>2013</b> , 121, 2175-85	2.2	109
195	Nonhepatosplenic T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 1214-25	6.7	107
194	Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. <i>Blood</i> , <b>2002</b> , 100, 1810-6	2.2	102
193	Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 102-8	7.1	94
192	The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. <i>Hepatology</i> , <b>2006</b> , 44, 44-52	11.2	94
191	Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. <i>Blood</i> , <b>2003</b> , 101, 2328-34	2.2	93
190	The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. <i>Blood</i> , <b>2011</b> , 117, 1270-9	2.2	91
189	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2831-2841	12.9	88
188	Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 501-10	5.8	86
187	Involvement of CED-3/ICE Proteases in the Apoptosis of B-Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , <b>1997</b> , 89, 3378-3384	2.2	85
186	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , <b>2014</b> , 123, 3790-6	2.2	82
185	Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1472-9	2.2	80
184	CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. <i>Cancer Research</i> , <b>2005</b> , 65, 2199-206	10.1	80
183	Selective inhibition of I $\kappa$ B kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. <i>Journal of Immunology</i> , <b>2007</b> , 178, 1923-30	5.3	75
182	Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). <i>American Journal of Pathology</i> , <b>2002</b> , 161, 957-68	5.8	75
181	In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2046-54	12.9	73
180	MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. <i>Cancer Research</i> , <b>2009</b> , 69, 7071-8	10.1	72
179	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , <b>1998</b> , 100, 142-6	4.5	72

178	Mechanism of action and resistance to monoclonal antibody therapy. <i>Seminars in Oncology</i> , <b>2003</b> , 30, 424-33	5.5	71
177	Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3956-68	12.9	67
176	Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. <i>Cancer Research</i> , <b>2008</b> , 68, 10178-86	10.1	64
175	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. <i>British Journal of Haematology</i> , <b>2007</b> , 136, 590-6	4.5	63
174	Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. <i>Genes Chromosomes and Cancer</i> , <b>2004</b> , 40, 140-5	5	63
173	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. <i>Journal of Pathology</i> , <b>2005</b> , 205, 507-13	9.4	62
172	Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 6907-15	12.9	61
171	The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. <i>Haematologica</i> , <b>2007</b> , 92, 308-14	6.6	61
170	Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 1310-22	6.7	61
169	CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. <i>Blood</i> , <b>2002</b> , 100, 4602-8	2.2	61
168	Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 72-4	13.4	59
167	Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. <i>Haematologica</i> , <b>2006</b> , 91, 11-6	6.6	57
166	Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. <i>Haematologica</i> , <b>2006</b> , 91, 895-902	6.6	57
165	Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis. <i>American Journal of Surgical Pathology</i> , <b>2004</b> , 28, 849-58	6.7	55
164	Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. <i>Blood</i> , <b>2020</b> , 136, 1419-1432	2.2	53
163	Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. <i>Genes Chromosomes and Cancer</i> , <b>2012</b> , 51, 881-9	5	51
162	Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5278-89	12.9	49
161	Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 4032-9	2.2	49

160	The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. <i>Oncotarget</i> , <b>2015</b> , 6, 22734-49	3.3	49
159	Recurrent mutations of NOTCH genes in follicular lymphoma identify a distinctive subset of tumours. <i>Journal of Pathology</i> , <b>2014</b> , 234, 423-30	9.4	48
158	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , <b>2011</b> , 96, 1470-7	6.6	48
157	Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. <i>Blood</i> , <b>2009</b> , 114, 1563-75	2.2	46
156	The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 2601-10	5.8	45
155	Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , <b>2011</b> , 35, 1014-9	2.7	44
154	MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2755-64	12.9	42
153	Control of chronic lymphocytic leukemia development by clonally-expanded CD8 T-cells that undergo functional exhaustion in secondary lymphoid tissues. <i>Leukemia</i> , <b>2019</b> , 33, 625-637	10.7	42
152	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , <b>2010</b> , 95, 1317-24	6.6	41
151	ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 726-34	12.9	40
150	Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. <i>Leukemia Research</i> , <b>2006</b> , 30, 923-34	2.7	40
149	The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. <i>Haematologica</i> , <b>2013</b> , 98, 1739-47	6.6	38
148	Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 938-48	5.5	38
147	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 501-507	13.4	37
146	NF-kappaB as a therapeutic target in chronic lymphocytic leukemia. <i>Expert Opinion on Therapeutic Targets</i> , <b>2010</b> , 14, 275-88	6.4	37
145	Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. <i>Annals of Hematology</i> , <b>2008</b> , 87, 269-76	3	36
144	Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. <i>Experimental Hematology</i> , <b>2003</b> , 31, 204-10	3.1	35
143	Molecular lymph node staging in bladder urothelial carcinoma: impact on survival. <i>European Urology</i> , <b>2008</b> , 54, 1363-72	10.2	34

142	Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma. <i>Leukemia and Lymphoma</i> , <b>2003</b> , 44, 71-6	1.9	33
141	Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. <i>Oncotarget</i> , <b>2014</b> , 5, 6788-800	3.3	31
140	Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. <i>Modern Pathology</i> , <b>2015</b> , 28, 1435-47	9.8	29
139	B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. <i>British Journal of Haematology</i> , <b>2014</b> , 164, 570-8	4.5	29
138	Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , <b>2002</b> , 99, 1873-4	2.2	29
137	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1493-1505	12.9	28
136	The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. <i>Haematologica</i> , <b>2014</b> , 99, 873-80	6.6	28
135	p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective I $\kappa$ B kinase inhibitor BMS-345541. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2767-76	12.9	28
134	Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 3754-61	12.9	28
133	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2019</b> , 104, 576-586	6.6	28
132	Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. <i>Haematologica</i> , <b>2014</b> , 99, e231-4	6.6	27
131	Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. <i>American Journal of Hematology</i> , <b>2007</b> , 82, 849-51	7.1	26
130	Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. <i>Genes Chromosomes and Cancer</i> , <b>2008</b> , 47, 1086-97	5	26
129	High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , <b>2003</b> , 147, 36-43		25
128	Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 717-22	1.9	25
127	Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. <i>American Journal of Clinical Pathology</i> , <b>2000</b> , 114, 786-92	1.9	25
126	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. <i>American Journal of Surgical Pathology</i> , <b>2016</b> , 40, 192-201	6.7	24
125	Routine use of immunophenotype by flow cytometry in tissues with suspected hematological malignancies <b>2003</b> , 56, 8-15		24

124	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. <i>Haematologica</i> , <b>2008</b> , 93, 207-14	6.6	23
123	Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. <i>Oncogene</i> , <b>2004</b> , 23, 8941-9	9.2	22
122	Increased incidence of acute myeloid leukemia after liver transplantation? Description of three new cases and review of the literature. <i>Transplantation</i> , <b>2004</b> , 77, 311-3	1.8	22
121	Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. <i>Haematologica</i> , <b>2020</b> , 105, 2205-2217	6.6	21
120	Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib). <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3458-71	12.9	21
119	CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. <i>Experimental Hematology</i> , <b>2002</b> , 30, 824-30	3.1	21
118	Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 393-403	12.9	20
117	Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma. <i>Autophagy</i> , <b>2013</b> , 9, 115-7	10.2	20
116	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 764-771	4.5	19
115	Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 586-97	12.9	19
114	In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. <i>Modern Pathology</i> , <b>2014</b> , 27, 1599-611	9.8	19
113	Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. <i>Pathology International</i> , <b>2006</b> , 56, 440-8	1.8	19
112	Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 112	22.4	19
111	Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , <b>2015</b> , 54, 668-80	5	18
110	Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. <i>Haematologica</i> , <b>2017</b> , 102, e360-e363	6.6	17
109	Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma. <i>Cancer Cell</i> , <b>2014</b> , 25, 7-9	24.3	17
108	4-Amino-2-aryl-amino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies. <i>European Journal of Medicinal Chemistry</i> , <b>2014</b> , 86, 664-75	6.8	17
107	Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells. <i>Haematologica</i> , <b>2012</b> , 97, 943-51	6.6	17



106	Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. <i>Haematologica</i> , <b>2008</b> , 93, 1843-51	6.6	17
105	Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma. <i>Oncotarget</i> , <b>2014</b> , 5, 726-39	3.3	17
104	Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2020</b> , 34, 100-114	10.7	17
103	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. <i>Blood Advances</i> , <b>2020</b> , 4, 5652-5665	7.8	16
102	β-thalassaemia due to a single codon deletion in the β-globin gene. Computational structural analysis of the new β-chain variant. <i>Human Mutation</i> , <b>1998</b> , 11, 412-412	4.7	16
101	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. <i>Haematologica</i> , <b>2020</b> , 105, 1032-1041	6.6	16
100	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. <i>Haematologica</i> , <b>2019</b> , 104, 778-788	6.6	15
99	Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. <i>Annals of Hematology</i> , <b>2017</b> , 96, 81-85	3	15
98	Surface adenosine deaminase. A novel B-cell marker in chronic lymphocytic leukemia. <i>Human Immunology</i> , <b>1995</b> , 42, 265-73	2.3	15
97	Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2011</b> , 30, 1324-40	1.4	14
96	Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , <b>2003</b> , 141, 114-9		14
95	Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 4132-4147	15.9	14
94	Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. <i>Oncogene</i> , <b>2020</b> , 39, 1185-1197	9.2	14
93	Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. <i>Nature Communications</i> , <b>2021</b> , 12, 651	17.4	14
92	Clonal evolution in chronic lymphocytic leukemia: analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 920-7	5	13
91	Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 2064-8	1.9	13
90	Independent origin of single and double mutations in the human glucose 6-phosphate dehydrogenase gene. <i>Human Mutation</i> , <b>1996</b> , 8, 311-8	4.7	13
89	CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 5507-20	3.3	13

88	Cellular Ontogeny and Hierarchy Influence the Reprogramming Efficiency of Human B Cells into Induced Pluripotent Stem Cells. <i>Stem Cells</i> , <b>2016</b> , 34, 581-7	5.8	13
87	Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 52-61	4.5	12
86	Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2019</b> , 38, 446	12.8	12
85	The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor- $\kappa$ B mutational status. <i>Haematologica</i> , <b>2017</b> , 102, e447-e451	6.6	12
84	First description of a frameshift mutation in the alpha1-globin gene associated with alpha-thalassaemia. <i>British Journal of Haematology</i> , <b>1997</b> , 98, 47-50	4.5	12
83	PI3K inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax. <i>Blood Advances</i> , <b>2020</b> , 4, 4217-4231	7.8	12
82	Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 557-561	4.5	11
81	Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2008</b> , 93, 132-6	6.6	11
80	Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , <b>2006</b> , 166, 89-93		11
79	Combined assay of adenosine deaminase, purine nucleoside phosphorylase, and lactate dehydrogenase in the early clinical evaluation of B-chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , <b>1988</b> , 27, 157-62	7.1	11
78	Cytotoxic effects of B lymphocytes mediated by reactive oxygen species. <i>Current Pharmaceutical Design</i> , <b>2004</b> , 10, 841-53	3.3	10
77	The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. <i>Leukemia</i> , <b>2021</b> , 35, 2635-2649	10.7	10
76	Expression and mutational analyses of KIT and PDGFR-alpha in sarcomatoid renal cell carcinoma. <i>Histopathology</i> , <b>2009</b> , 55, 230-2	7.3	9
75	Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. <i>Leukemia Research</i> , <b>2005</b> , 29, 595-7	2.7	9
74	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. <i>Oncotarget</i> , <b>2013</b> , 4, 1931-2	3.3	9
73	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 89-95	13.4	9
72	Fluorescent nucleoside derivatives as a tool for the detection of concentrative nucleoside transporter activity using confocal microscopy and flow cytometry. <i>Molecular Pharmaceutics</i> , <b>2015</b> , 12, 2158-66	5.6	8
71	IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. <i>Nature Communications</i> , <b>2020</b> , 11, 3390	17.4	8

70	Multiple forms of protein kinase CK2 present in leukemic cells: In vitro study of its origin by proteolysis. <i>Molecular and Cellular Biochemistry</i> , <b>1999</b> , 191, 229-234	4.2	8
69	Chronic nonspherocytic hemolytic anemia (CNSHA) and glucose 6 phosphate dehydrogenase (G6PD) deficiency in a patient with familial amyloidotic polyneuropathy (FAP). Molecular study of a new variant (G6PD Clinic) with markedly acidic pH optimum. <i>Human Genetics</i> , <b>1989</b> , 81, 161-4	6.3	8
68	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 TCF-1 CD8 T cell population that sustains anti-tumor immunity. <i>Immunity</i> , <b>2021</b> ,	32.3	8
67	Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. <i>Oncotarget</i> , <b>2015</b> , 6, 21159-72	3.3	8
66	Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 2762-2773	7.5	8
65	Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. <i>Annals of Hematology</i> , <b>2014</b> , 93, 797-802	3	7
64	A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2012</b> , 156, 612-8	4.5	7
63	Quantitative assessment of PML-RARa and BCR-ABL by two real-time PCR instruments: multiinstitutional laboratory trial. <i>Clinical Chemistry</i> , <b>2004</b> , 50, 1088-92	5.5	7
62	TBET-expressing Th1 CD4 T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in E $\mu$ -TCL1 mice. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 133-145	4.5	7
61	EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 2311-2324	10.7	7
60	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , <b>2017</b> , 96, 639-646	3	6
59	Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 3081-3089	4.9	6
58	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.. <i>Blood Advances</i> , <b>2021</b> ,	7.8	6
57	Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 147-150	4.5	5
56	A putative "hepitype" in the ATM gene associated with chronic lymphocytic leukemia risk. <i>Genes Chromosomes and Cancer</i> , <b>2011</b> , 50, 887-95	5	5
55	Molecular biology in acute leukemia. <i>Clinical and Translational Oncology</i> , <b>2006</b> , 8, 550-9	3.6	5
54	Obatoclax (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma.. <i>Blood</i> , <b>2006</b> , 108, 832-832	2.2	5
53	Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL. <i>Blood</i> , <b>2013</b> , 122, 378-378	2.2	5

52	Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and Hampers Leukemia-Microenvironment Interactions. <i>Blood</i> , <b>2014</b> , 124, 4680-4680	2.2	5
51	An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 2059-2066	4.9	4
50	Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. <i>Leukemia Research</i> , <b>2011</b> , 35, 1276-8	2.7	4
49	EOMES is essential for antitumor activity of CD8 T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 3152-3162	10.7	4
48	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , <b>2019</b> , 98, 2319-2328	3	3
47	Refining the diagnosis and prognostic categorization of acute myeloid leukemia patients with an integrated use of cytogenetic and molecular studies. <i>Acta Haematologica</i> , <b>2013</b> , 129, 65-71	2.7	3
46	Stability of Conversion Factors for BCR-ABL Monitoring -Implications for the Frequency of Validation Rounds. <i>Blood</i> , <b>2010</b> , 116, 893-893	2.2	3
45	Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell NonHodgkin Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 3935-3935	2.2	3
44	Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 755-757	4.5	3
43	New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. <i>Expert Opinion on Drug Discovery</i> , <b>2017</b> , 12, 1041-1052	6.2	2
42	Follicular Dendritic Cells Deliver Angiogenesis Signaling To Follicular Lymphoma Cells That Is Hampered By The Pan-PI3K Inhibitor NVP-BKM120. <i>Blood</i> , <b>2013</b> , 122, 3072-3072	2.2	2
41	Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 1217-1224	5.1	2
40	Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. <i>Scientific Reports</i> , <b>2020</b> , 10, 22153	4.9	2
39	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2318-2326	1.9	2
38	Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
37	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	2
36	Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin?. <i>Haematologica</i> , <b>2020</b> , 105, e484	6.6	1
35	CXCR5-mediated shaping of the lymphoid follicle in chronic lymphocytic leukemia. <i>Cancer Discovery</i> , <b>2014</b> , 4, 1374-6	24.4	1

34	BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.. <i>Blood</i> , <b>2007</b> , 110, 3464-3464	2.2	1
33	BAFF and APRIL in Chronic Lymphocytic Leukemia: Clinico-Biological Correlates and Prognostic Significance.. <i>Blood</i> , <b>2009</b> , 114, 1235-1235	2.2	1
32	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. <i>Oncotarget</i> , <b>2013</b> , 4, 1919-1932	3.3	1
31	Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation		1
30	Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , <b>1998</b> , 92, 1406-1414	2.2	1
29	Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases. <i>Blood</i> , <b>2014</b> , 124, 1677-1677	2.2	1
28	Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
27	The History of 34 Errors Identified in 874 Patients Analyzed at Weekly Clinical-Pathological Meetings in Two Institutions over 22 Years (1982-2004).. <i>Blood</i> , <b>2004</b> , 104, 5287-5287	2.2	0
26	Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia. <i>Blood</i> , <b>2021</b> , 138, 462-462	2.2	0
25	Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 1020-1025	4.5	0
24	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. <i>Blood</i> , <b>2010</b> , 116, 894-894	2.2	0
23	The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 1647-1647	2.2	0
22	Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , <b>2022</b> , 61, 37-43	5	0
21	NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12. <i>Genes Chromosomes and Cancer</i> , <b>2012</b> , 51, 1064-1065	5	
20	Reply to Schmidt MYST3/CREBBP (MOZ/CBP) and CREBBP/MYST3(CBP/MOZ) Transcripts in AML with t(8;16)(p11;p13) <i>Genes Chromosomes and Cancer</i> , <b>2005</b> , 42, 209-209	5	
19	Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.. <i>Blood</i> , <b>2004</b> , 104, 2054-2054	2.2	
18	Equilibrative Nucleoside Transporter-2 (ENT2) Protein Correlates with Ex-Vivo Sensitivity to Fludarabine in Chronic Lymphocytic Leukemia (CLL)-Cells.. <i>Blood</i> , <b>2004</b> , 104, 2079-2079	2.2	
17	Severe Myelodysplasia with Monosomy 7 Developing during Imatinib Treatment of Philadelphia-Positive Chronic Myeloid Leukemia: Two Cases Evolving with Different Outcome.. <i>Blood</i> , <b>2005</b> , 106, 4861-4861	2.2	

16	c-FLIP Level Determines the Sensitivity of Mantle Cell Lymphoma Cells to TRAIL-Induced Apoptosis Following Inhibition of NFκB Signalling or Proteasome Activity.. <i>Blood</i> , <b>2005</b> , 106, 4820-4820	2.2
15	Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.. <i>Blood</i> , <b>2005</b> , 106, 3009-3009	2.2
14	Tissue Factor and Soluble Markers of Platelet and Endothelial Activation in Essential Thrombocythemia: Relationship with Thrombosis and JAK2 V617F Mutation Status.. <i>Blood</i> , <b>2006</b> , 108, 2707-2707	2.2
13	FLT3 Mutations in a Large Series of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.. <i>Blood</i> , <b>2006</b> , 108, 2348-2348	2.2
12	Essential Thrombocythemia in Young Individuals: Frequency and Risk Factors for Vascular Events and Evolution to Myelofibrosis in 126 Patients.. <i>Blood</i> , <b>2006</b> , 108, 3598-3598	2.2
11	JAK2 Mutations at Exon 12 and 14 in Polycythemia Vera and Idiopathic Erythrocytosis: Incidence and Correlation with Clinical Characteristics.. <i>Blood</i> , <b>2007</b> , 110, 2532-2532	2.2
10	Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 2650-2650	2.2
9	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. <i>Blood</i> , <b>2018</b> , 132, 4299-4299	2.2
8	Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol). <i>Blood</i> , <b>2018</b> , 132, 1385-1385	2.2
7	Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 4288-4288	2.2
6	Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms. <i>Blood</i> , <b>2015</b> , 126, 3902-3902	2.2
5	Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.. <i>Blood</i> , <b>2009</b> , 114, 1113-1113	2.2
4	Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms. <i>Blood</i> , <b>2010</b> , 116, 625-625	2.2
3	The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 3918-3918	2.2
2	B Cell Stimulation through BCR and CD40 Modulates the Response of Chronic Lymphocytic Leukemia Cells to BAFF and APRIL.. <i>Blood</i> , <b>2010</b> , 116, 1361-1361	2.2
1	Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 252-254	13.4